Alyeska Investment Group
KLRS

Alyeska Investment Group’s Kalaris Therapeutics KLRS Stock Holding History

Alyeska Investment Group’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.33M Hold
572,687
– – 0.01% 563
2026
Q1 		$3.27M Buy
572,687
+169,136
+42% +$1.5M 0.01% 519
2025
Q4 		$3.4M Buy
+403,551
New +$2.58M 0.01% 488
2023
Q3 		– Sell
-17,391
Closed -$1.36M – 648
2023
Q2 		$1.36M Buy
+17,391
New +$1.65M 0.01% 434

Other funds holding KLRS

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Alyeska Investment Group's KLRS Position: Q2 2026 in Review

Alyeska Investment Group held its Kalaris Therapeutics (KLRS) position steady in Q2 2026 at 572,687 shares worth $2.33M. The position accounts for 0.01% of the portfolio, ranked #563.

Alyeska Investment Group first reported a position in KLRS in Q2 2023 and has held it in 4 quarters since. The position peaked at $3.4M in Q4 2025. 57 funds tracked by Wall St. Rank hold KLRS as of Q2 2026.

  • Alyeska Investment Group held 572,687 shares of Kalaris Therapeutics worth $2.33M as of Q2 2026.
  • Alyeska Investment Group left its Kalaris Therapeutics share count unchanged in Q2 2026.
  • Kalaris Therapeutics made up 0.01% of Alyeska Investment Group's portfolio in Q2 2026, its #563 holding.
  • Alyeska Investment Group first reported a position in Kalaris Therapeutics in Q2 2023 and has held it in 4 quarters since.
  • Alyeska Investment Group's Kalaris Therapeutics position peaked at $3.4M in Q4 2025.
  • 57 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q2 2026.

Based on Alyeska Investment Group's 13F filing for Q2 2026, filed 14 Aug 2026.